- Home
- EPAM vs LEGN Comparison
EPAM vs LEGN Comparison
Compare EPAM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- LEGN
- Stock Information
- Founded
- EPAM 1993
- LEGN 2014
- Country
- EPAM United States
- LEGN United States
- Employees
- EPAM N/A
- LEGN N/A
- Industry
- EPAM EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- LEGN Health Care
- Exchange
- EPAM Nasdaq
- LEGN Nasdaq
- Market Cap
- EPAM 8.2B
- LEGN 7.0B
- IPO Year
- EPAM 2012
- LEGN 2020
- Fundamental
- Price
- EPAM $180.18
- LEGN $27.91
- Analyst Decision
- EPAM Buy
- LEGN Strong Buy
- Analyst Count
- EPAM 16
- LEGN 13
- Target Price
- EPAM $229.00
- LEGN $75.67
- AVG Volume (30 Days)
- EPAM 735.5K
- LEGN 1.5M
- Earning Date
- EPAM 05-08-2025
- LEGN 05-13-2025
- Dividend Yield
- EPAM N/A
- LEGN N/A
- EPS Growth
- EPAM N/A
- LEGN N/A
- EPS
- EPAM 7.15
- LEGN N/A
- Revenue
- EPAM $4,864,167,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EPAM $14.70
- LEGN $65.96
- Revenue Next Year
- EPAM $7.82
- LEGN $52.55
- P/E Ratio
- EPAM $25.83
- LEGN N/A
- Revenue Growth
- EPAM 4.72
- LEGN 112.46
- 52 Week Low
- EPAM $138.15
- LEGN $29.27
- 52 Week High
- EPAM $269.00
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EPAM 58.42
- LEGN 28.84
- Support Level
- EPAM $156.21
- LEGN $27.43
- Resistance Level
- EPAM $189.62
- LEGN $33.30
- Average True Range (ATR)
- EPAM 4.40
- LEGN 1.77
- MACD
- EPAM 3.27
- LEGN -0.58
- Stochastic Oscillator
- EPAM 68.44
- LEGN 2.18
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.